Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.1.1 (
hexokinase
)
5,274
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Complexes made up of the kinases,
hexokinase
and glycerol kinase, together with the outer mitochondrial membrane voltage-dependent anion channel (VDAC) protein, porin, and the inner mitochondrial membrane protein, the adenine nucleotide translocator, are involved in tumorigenesis, diabetes mellitus, and central nervous system function. Identification of these two mitochondrial membrane proteins, along with an 18 kD protein, as components of the
peripheral benzodiazepine receptor
, provides independent confirmation of the interaction of porin and the adenine nucleotide translocator to form functional contact sites between the inner and outer mitochondrial membranes. We suggest that these are dynamic structures, with channel conductances altered by the presence of ATP, and that ligand-mediated conformational changes in the porin-adenine nucleotide translocator complexes may be a general mechanism in signal transduction.
...
PMID:Microcompartmentation of energy metabolism at the outer mitochondrial membrane: role in diabetes mellitus and other diseases. 807 85
Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug. In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity. In cell culture (PC-12 and neuroblastoma SH-SY5Y cells) it exhibits neuroprotective and anti-apoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia. In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery. The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties. Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. They also antagonize scopolamine-induced impairments in spatial memory. In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test. This is associated with an increase in brain levels of serotonin. The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore. The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glyceraldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus. The latter processes are closely associated with neurotoxin-induced apoptosis. Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic
peripheral benzodiazepine receptor
, which together with Bcl-2,
hexokinase
, porin, and adenine nucleotide translocator constitutes part of the VDAC. Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus. This process has been shown to involve the upregulation of PKC and MAP kinase. It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.
...
PMID:Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. 1204 33
The mitochondrial 18kDa Translocation Protein (TSPO) was first identified in 1977 by its capability to bind benzodiazepines in peripheral tissues. It is more commonly known after its previous name -
peripheral benzodiazepine receptor
(
PBR
) as opposed to the central benzodiazepine receptor (CBR), from which it differs by location, structure and function. It is ubiquitous with highest expression in steroid-producing tissues, like adrenal cortex, ovaries, testicles, and placenta. The role of TSPO is crucial for living; its inactivation results in early embryonic-lethal phenotype in mice. TSPO has been implicated in various functions of cell, including steroidogenesis, cellular respiration, reactive oxygen species production, heme biosynthesis, immunomodulation, apoptosis, and cellular proliferation. TSPO has been shown to interact with other cellular proteins: 32 kDa voltage-dependent anion channel (VDAC), 30 kDa adenine nucleotide translocase (ANT), cyclophilin D,
hexokinase
, creatinine kinase, diazepam binding inhibitor (DBI), phosphate carrier and Bcl-2 family. They are - involved in the formation and regulation of mitochondrial permeability transition pore (mPTP) at the junction of the inner and outer mitochondrial membranes. While the function and characteristics of the mPTP are known, its well defined, but its structure remains speculative. Changes in TSPO expression are associated with multiple disorders, including cancer, ischaemia-reperfusion injury, neurological diseases and psychiatric disorders, atheromatosis, and others. - TSPO is able to bind cholesterol, porphyrins and other ligands with different affinity. The current knowledge of TSPO implicates its potential use as a diagnostic marker and therapeutic target in different diseases and their therapies.
...
PMID:[18 kDa translocator protein--implications in cell's functions]. 2558 12